Deciphera Pharmaceuticals Inc (DCPH)
25.47
+0.02
(+0.08%)
USD |
NASDAQ |
May 20, 14:33
Deciphera Pharmaceuticals Enterprise Value: 1.929B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.929B |
| May 16, 2024 | 1.928B |
| May 15, 2024 | 1.928B |
| May 14, 2024 | 1.927B |
| May 13, 2024 | 1.926B |
| May 10, 2024 | 1.921B |
| May 09, 2024 | 1.921B |
| May 08, 2024 | 1.921B |
| May 07, 2024 | 1.922B |
| May 06, 2024 | 1.921B |
| May 03, 2024 | 1.814B |
| May 02, 2024 | 1.814B |
| May 01, 2024 | 1.813B |
| April 30, 2024 | 1.805B |
| April 29, 2024 | 1.806B |
| April 26, 2024 | 932.08M |
| April 25, 2024 | 893.44M |
| April 24, 2024 | 929.62M |
| April 23, 2024 | 933.73M |
| April 22, 2024 | 925.35M |
| April 19, 2024 | 932.74M |
| April 18, 2024 | 896.59M |
| April 17, 2024 | 936.85M |
| April 16, 2024 | 946.71M |
| April 15, 2024 | 951.64M |
| Date | Value |
|---|---|
| April 12, 2024 | 963.96M |
| April 11, 2024 | 1.003B |
| April 10, 2024 | 1.010B |
| April 09, 2024 | 1.012B |
| April 08, 2024 | 960.68M |
| April 05, 2024 | 987.79M |
| April 04, 2024 | 971.36M |
| April 03, 2024 | 983.68M |
| April 02, 2024 | 975.46M |
| April 01, 2024 | 1.022B |
| March 31, 2024 | 1.020B |
| March 28, 2024 | 964.77M |
| March 27, 2024 | 920.33M |
| March 26, 2024 | 891.24M |
| March 25, 2024 | 930.03M |
| March 22, 2024 | 924.37M |
| March 21, 2024 | 946.19M |
| March 20, 2024 | 966.39M |
| March 19, 2024 | 903.36M |
| March 18, 2024 | 893.67M |
| March 15, 2024 | 953.46M |
| March 14, 2024 | 979.31M |
| March 13, 2024 | 984.97M |
| March 12, 2024 | 993.86M |
| March 11, 2024 | 1.030B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
108.03M
Minimum
Nov 29 2021
3.223B
Maximum
Nov 16 2020
1.286B
Average
965.58M
Median
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 135.32B |
| Dynavax Technologies Corp | 953.65M |
| Gilead Sciences Inc | 104.76B |
| Esperion Therapeutics Inc | 482.55M |
| SINTX Technologies Inc | 4.900M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.08M |
| Revenue (Quarterly) | 45.00M |
| Total Expenses (Quarterly) | 93.85M |
| EPS Diluted (Quarterly) | -0.52 |
| Gross Profit Margin (Quarterly) | 95.36% |
| Profit Margin (Quarterly) | -100.2% |
| Earnings Yield | -8.68% |
| Normalized Earnings Yield | -8.677 |